Investigating how arsenic exposure may lead to diabetes in American Indian communities.
The Epitranscriptome as a Novel Mechanism of Arsenic-Induced Diabetes.
This study is looking at how exposure to arsenic might be linked to higher rates of type 2 diabetes in American Indian communities, focusing on how it affects the body's insulin-producing cells and a specific RNA modification that could help us understand diabetes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10975361 on NIH RePORTER |
What this research studies
This research explores the connection between arsenic exposure and the high rates of type 2 diabetes mellitus (T2DM) in American Indian communities. It focuses on understanding how arsenic induces oxidative stress and inflammation, which can lead to dysfunction in insulin-producing cells. The study will investigate a specific RNA modification, N6-methyladenosine (m6A), which plays a role in cellular responses to stress and may influence diabetes development. By examining the mechanisms of m6A in relation to arsenic exposure, the research aims to uncover new insights into diabetes pathogenesis.
Who could benefit from this research
Good fit: Ideal candidates for this research are American Indian individuals aged 21 and older who are at risk for or have been diagnosed with type 2 diabetes.
Not a fit: Patients who do not belong to American Indian communities or those without exposure to arsenic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating diabetes in populations affected by arsenic exposure.
How similar studies have performed: Previous studies have shown promising results in understanding the role of epitranscriptomic modifications in diabetes, suggesting that this approach may yield valuable insights.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Navas-Acien, Ana — Columbia University Health Sciences
- Study coordinator: Navas-Acien, Ana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.